JP2013533227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533227A5 JP2013533227A5 JP2013513645A JP2013513645A JP2013533227A5 JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5 JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013513645 A JP2013513645 A JP 2013513645A JP 2013533227 A5 JP2013533227 A5 JP 2013533227A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- fgf21
- acetylamino
- des181
- conh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 23
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 23
- 102220047964 rs587783194 Human genes 0.000 claims 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- -1 17-carboxyheptadecanoylamino Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2010/057986 | 2010-06-08 | ||
| PCT/EP2010/057986 WO2010142665A1 (en) | 2009-06-11 | 2010-06-08 | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| CN2010001099 | 2010-07-21 | ||
| CN2010/001099 | 2010-07-21 | ||
| US37329010P | 2010-08-13 | 2010-08-13 | |
| US61/373,290 | 2010-08-13 | ||
| PCT/EP2011/059273 WO2011154349A2 (en) | 2010-06-08 | 2011-06-06 | Fgf21 analogues and derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533227A JP2013533227A (ja) | 2013-08-22 |
| JP2013533227A5 true JP2013533227A5 (cg-RX-API-DMAC7.html) | 2014-07-24 |
Family
ID=49179102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513645A Withdrawn JP2013533227A (ja) | 2010-06-08 | 2011-06-06 | Ｆｇｆ２１類似体および誘導体 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2013533227A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011154349A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| WO2013188182A1 (en) * | 2012-06-11 | 2013-12-19 | Eli Lilly And Company | Fibroblast growth factor 21 variants |
| TWI513705B (zh) * | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| DK2938740T3 (da) | 2012-12-27 | 2022-06-20 | Ngm Biopharmaceuticals Inc | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser |
| WO2015065897A1 (en) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
| WO2015103782A1 (en) * | 2014-01-13 | 2015-07-16 | Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co | Fgf21 mutant and conjugate thereof |
| CN106662577B (zh) | 2014-01-24 | 2020-07-21 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016065106A1 (en) | 2014-10-23 | 2016-04-28 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| UY36370A (es) | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Polipéptidos fgf-21 modificados y sus usos |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| HK1246156B (en) * | 2014-12-23 | 2020-03-27 | Novo Nordisk A/S | FGF21 derivatives and their uses |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| WO2017180988A2 (en) * | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
| US11318186B2 (en) * | 2016-05-25 | 2022-05-03 | Board Of Regents, The University Of Texas System | Use of FGF21 in methods of increasing exocrine pancreatic secretion |
| WO2017220706A1 (en) | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
| MX2019012331A (es) | 2017-04-21 | 2020-01-23 | Yuhan Corp | Metodo para producir proteinas de doble funcion y sus derivados. |
| JP2020533304A (ja) | 2017-09-08 | 2020-11-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 改変型線維芽細胞成長因子２１（ｆｇｆ−２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法 |
| RS65720B1 (sr) | 2017-12-22 | 2024-08-30 | Novartis Ag | Tretiranje metaboličkih poremećaja pomoću fgf21 varijanti |
| BR112020026512A2 (pt) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | Formulações de fgf-21 |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CN115243725A (zh) | 2020-01-08 | 2022-10-25 | 百时美施贵宝公司 | Fgf-21缀合物配制品 |
| EP4192495A1 (en) | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| CN116162145A (zh) | 2021-09-08 | 2023-05-26 | 北京志道生物科技有限公司 | 一种fgf21突变蛋白及其应用 |
| KR20250031229A (ko) | 2022-06-03 | 2025-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 골수 유래된 성장 인자의 재조합 발현 |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| WO2025120204A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032678A1 (en) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| CA2557782A1 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| DE602005016917D1 (de) | 2004-05-13 | 2009-11-12 | Lilly Co Eli | Fgf-21-fusionsproteine |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EA011390B1 (ru) | 2004-09-02 | 2009-02-27 | Эли Лилли Энд Компани | Мутантные белки (мутеины) фактора роста фибробластов 21 |
| JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| WO2006078463A2 (en) | 2005-01-21 | 2006-07-27 | Eli Lilly And Company | Method for treating cardiovascular disease |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US20110034373A1 (en) * | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| SG195542A1 (en) * | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| ES2692495T3 (es) * | 2009-01-23 | 2018-12-03 | Novo Nordisk A/S | Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos |
| EP2440235A1 (en) * | 2009-06-11 | 2012-04-18 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
-
2011
- 2011-06-06 WO PCT/EP2011/059273 patent/WO2011154349A2/en not_active Ceased
- 2011-06-06 JP JP2013513645A patent/JP2013533227A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533227A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505146A5 (cg-RX-API-DMAC7.html) | ||
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| JP2012529463A5 (cg-RX-API-DMAC7.html) | ||
| JP2017500289A5 (cg-RX-API-DMAC7.html) | ||
| HRP20181026T1 (hr) | Dugodjelujuće formulacije inzulina | |
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| UA114700C2 (uk) | Тверда фармацевтична форма для перорального застосування та процес її виготовлення | |
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| JP2013530974A5 (cg-RX-API-DMAC7.html) | ||
| WO2009011544A3 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| JP2015513544A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140480T1 (hr) | Pegilirani spojevi inzulina lispro | |
| CY1117576T1 (el) | Δινουκλεοτιδικα προφαρμακα | |
| EA201100969A1 (ru) | Солевые формы органического соединения | |
| WO2009033770A3 (en) | Calcitonin c-terminal flanking peptide for use as a therapeutic agent | |
| WO2009033793A3 (en) | Pentagastrin as a therapeutic agent | |
| WO2009043466A3 (en) | Therapeutic use of the peptide gluten exorphin a5 | |
| WO2009033718A3 (en) | Use of anti -inflammatory peptide 1 as a therapeutic agent | |
| TNSN07447A1 (en) | Treatment of liver diseases in which iron plays a role in pathogenesis | |
| RU2016135543A (ru) | Новые производные инсулина и их применение в медицине | |
| ATE520406T1 (de) | Kristalline form des ibandronat-natriums | |
| JP2017508741A5 (cg-RX-API-DMAC7.html) | ||
| JP2011046708A5 (cg-RX-API-DMAC7.html) | ||
| WO2009046858A3 (en) | Therapeutic uses of kisspeptin 13 and compositions thereof |